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Abstract Cytosolic 50 nucleotidase II (cN-II) catalyses
both the hydrolysis of a number of nucleoside mono-
phosphates (e.g., IMP + H2O→ inosine + Pi), and the
phosphate transfer from a nucleoside monophosphate donor
to the 50 position of a nucleoside acceptor (e.g., IMP +
guanosine → inosine + GMP). The enzyme protein
functions through the formation of a covalent phosphoen-
zyme intermediate, followed by the phosphate transfer
either to water (phosphatase activity) or to a nucleoside
(phosphotransferase activity). It has been proposed that cN-
II regulates the intracellular concentration of IMP and GMP
and the production of uric acid. The enzyme might also
have a potential therapeutic importance, since it can
phosphorylate some anti-tumoral and antiviral nucleoside
analogues that are not substrates of known kinases. In this
review we summarise our recent studies on the structure,
regulation and function of cN-II. Via a site-directed
mutagenesis approach, we have identified the amino acids
involved in the catalytic mechanism and proposed a
structural model of the active site. A series of in vitro
studies suggests that cN-II might contribute to the regula-
tion of 5-phosphoribosyl-1-pyrophosphate (PRPP) level,
through the so-called oxypurine cycle, and in the produc-
tion of intracellular adenosine, formed by ATP degradation.
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Cytosolic 50-nucleotidase II (cN-II) belongs to a family of
proteins catalysing the hydrolysis of intracellular nucleo-
tides. Members of this family differ widely in cellular
location, substrate specificity, regulation and amino acid
sequence [1]. cN-II has been described as a bifunctional
enzyme, since it catalyses both the hydrolysis of IMP and
GMP and the transfer of phosphate group from a
mononucleotide donor to a nucleoside acceptor such as
inosine, guanosine, deoxyinosine and several nucleoside
analogues in use as antiviral or antineoplastic purine
prodrugs [2, 3]. Furthermore, it seems to be responsible of
the resistance to several purine derivative drugs. Therefore,
its activity has been indicated as predictive of patient
survival in acute myeloid leukaemia [4, 5]. The bovine
recombinant enzyme presents a 99% amino acid identity
with human cN-II [6]. In previous work we have shown
that the enzyme catalyses the hydrolase/phosphotransferase
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reaction through the formation of a covalent enzyme–
phosphate intermediate and have described the complex
regulation of the enzyme activity, depending on intracellu-
lar energy charge [7, 8]. Here, we report our more recent
results obtained on the structure, function, and role of this
intriguing enzyme. By a site-directed mutagenesis approach
we have identified the amino acid residues involved in the
catalytic mechanism and proposed a structural model of the
active site [9]. In vitro results suggest that cN-II might be
involved also in the regulation of PRPP (5-phosphoribosyl-
1-pyrophosphate) concentration [10] and in the production
of intracellular adenosine, formed by ATP degradation [11].
Enzyme distribution, purification and kinetics
The existence of cytosolic 50-nucleotidase was first reported
in the liver of some vertebrates such as chicken, rat, pig and
frog. Subsequently, its existence in chicken heart, rat heart
and kidney, pig lung and several human tissues, such as
malignant lymphocytes, placenta, erythrocytes, lympho-
blasts and colon carcinoma, has been assessed by its
isolation from these tissues [12]. In mammals the activities,
revealed by immunotitration to eliminate the interference of
non-specific phosphatases and other nucleotidases, are high
in testis and spleen and low in skeletal muscle and
erythrocytes; in human tissues, specific activity is higher
in fibroblasts and granulocytes than in erythrocytes.
Furthermore, T and B lymphoblastoid cells display a higher
activity than do peripheral lymphocytes [13]. The cN-II
gene is located on chromosome 10 [4], and its mRNA is
ubiquitously expressed in human tissues. The specific
activity of cytosolic 50-nucleotidase is significantly in-
creased in human colon carcinoma extracts compared to
the activity measured in the apparently normal peritumoral
tissue from the same patients; this confirms the previous
observation that the enzyme is more expressed in cells with
active DNA synthesis and/or high turnover rate of nucleic
acids and their precursors [14]. cN-II has been purified
from many eukaryotic sources. The various enzymes
exhibit similar kinetic characteristics, substrate specificity
and regulation, despite the large differences reported in the
molecular mass [13]. The apparent molecular mass of the
enzyme estimated by gel filtration ranges from 165 kDa for
the Artemia enzyme [15] to 265 kDa for the pig lung
enzyme purified in the presence of protease inhibitors [16],
whereas the subunit molecular masses ranges from 51 kDA
to 62 kDa, indicating a tetrametric structure for 5-N. The
enzyme is specific for IMP (Km 0.1 mM), GMP and their
corresponding deoxy-derivatives. It is activated by ATP,
ADP, 2,3-bis-phosphoglycerate, decavanadate and, to a
smaller extent, by other nucleoside diphosphates and
triphosphates (Table 1). The enzyme activity depends on
adenylate energy charge and phosphate concentration. The
inhibition by inorganic phosphate (Pi) is counteracted by
ATP at physiological concentrations and, to a smaller
extent, by ADP [3, 6, 7]. In 1982 Worku and Newby [17]
proposed that the hydrolysis of the monophosphate pro-
ceeds via the formation of an enzyme–phosphate interme-
diate, as for many phosphate-transferring enzymes; this
hypothesis was based on kinetic evidence. The formation of
a phosphorylated intermediate was later demonstrated
directly by trapping the 32P-labelled phosphoenzyme,
followed by electrophoresis and autoradiography [7]. The
best phosphate acceptor in the phosphotransferase reaction
is inosine, with a Km of approximately 1 mM. The Km
values of calf thymus cN-II for both inosine and IMP were
unaffected by the presence of activators, while Vmax was
increased approximately 10 times. The inhibitor Pi causes a
Km increase of about 4 times for both substrates.
Enzyme structure
The expression of the cloned bovine cDNA led to a
recombinant protein with functional properties identical to
the protein purified from calf thymus. The coding nucleo-
tide sequences reveals a very high degree of similarity,
94%, to the coding region of the human cN-II [9]. The
recombinant bovine enzyme expressed and purified in E.
coli, being identical to human protein for functional and
regulatory properties and being an abundant source of cN-
II, has been selected as a source for our structural,
regulatory and functional studies. cN-II is the first member
of the cytosolic 50-nucleotidases whose reaction mechanism
has been elucidated [6, 7]. During catalysis, this enzyme
was demonstrated to become phosphorylated on the first
aspartate of its DMDYT sequence. A similar motif DXDX
(T/V) (motif I) is present in all members of the HAD (L-2-
haloacid dehalogenase) superfamily, where the nucleophilic
attack of this aspartate is essential for the catalytic
machinery [9, 18, 19]. P-type ATPase/phosphotransferase
members of the HAD superfamily share a similar structural
Table 1 Structural and functional characteristics of cN-II (SDS
sodium dodecyl sulphate, BPG bis-phosphoglycerate).
Distribution Ubiquitous
MW subunit
(SDS electrophoresis) 51–62 kDa
(predicted from mRNA) 66 kDa
Quaternary structure Tetramer
Substrates
IMP Km 0.1 mM
Inosine Km 1 mM
Activators: ATP, ADP, BPG At millimolar concentrations
Inhibitor: Pi At millimolar concentrations
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fold and a common reaction mechanism, which requires the
formation of a covalent enzyme–phosphate intermediate.
Furthermore, crystallographic and site-directed mutagenesis
studies on these proteins demonstrated that a series of other
common amino acids always occurs in their active site, thus
determining the occurrence of two additional sequence
motifs common to all members of the HAD family. The
first one (motif II) is characterised by a threonine/serine
residue included in a hydrophobic region; the second one
(motif III) presents a conserved lysine and a pair of aspartic
acid residues (Table 2). Recently, the resolution of the
crystal structure of mdN, a dimeric mitochondrial nucleo-
tidase specific for deoxynucleotides, has been reported,
demonstrating this enzyme as the first example of a 50-
nucleotidase belonging to the HAD superfamily [20]. On
this basis, a large number of proteins differing in catalytic
activity on various substrates, polypeptide length (from 200
to 1,400 amino acids), domain arrangement, oligomerisa-
tion and conformational change following ligand binding,
have been related to the HAD/P-type ATPases/phospho-
transferases superfold [21]. However, no structural data on
cN-II are available at the moment.
To verify the predicted role for the conserved residues
present in the three motifs of cN-II, 13 mutated cN-II
products were constructed and expressed. Extracts were
prepared 16 h after the addition of isopropylthiogalactoside,
and recombinant wild type and cN-II mutants were purified.
In all cases sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE) analysis showed a single
component, migrating with an apparent mass of 60 kDa.
Purified proteins were used in kinetics measurements.
Both conservative and non-conservative substitution of
D52 and D54 (motif I) completely abolished enzyme
activity and formation of cN-II-phosphate intermediate
[6]. Replacement at other positions of this motif strongly
affected cN-II function. In fact, substitution at position 56
(mutant T56R) resulted in a protein devoid of phosphatase
and phosphotransferase activities. In contrast, mutagenesis
of M53 had a less severe effect; however, while non-
conservative substitutions (M53N) caused only a strong
decrease in catalytic efficiency, conservative substitution
(M53I) determined effects both on enzyme activity and
affinity toward IMP. This latter mutant exhibited the lowest
phosphatase vs phosphotransferase activity ratio observed
so far; it also showed a sigmoidal dependence on Mg2+
concentration. These results indicate the essential role of
these residues for proper D52 and D54 orientation and
effective cN-II catalysis, confirming the function of motif I
as deduced by previous chemical labelling and site-directed
mutagenesis experiments.
The conserved amino acid present in motif II common to
all HAD superfamily members is always a serine or
threonine residue; this amino acid is important for a proper
orientation of the substrate within the active site through
specific hydrogen bonding. The sequence alignment of
HAD superfamily members indicated the T249 as an
essential residue for cN-II activity. However, another amino
acid (S251) with similar properties occurs closely in
motif II. In order to identify the residue present in
motif II unambiguously, we prepared conservative and
non-conservative mutants of both amino acids. Mutant
T249V showed strongly reduced enzyme activity and an
alteration of Km values for both substrates. In contrast, a
conservative substitution (mutant T249S) yielded kinetic
behaviour more similar to wild type enzyme. On the other
hand, the effect on enzyme activity exerted by non-
conservative mutation of residue 251 (mutant S251A) was
by far less pronounced than that produced by the
conservative S251T mutation. These results demonstrate
the essential role of the T249 hydroxyl group for cN-II
catalysis, confirming the nature of motif II deduced by
multiple sequence alignments.
Motif III in the HAD superfamily is characterised by the
presence of a conserved lysine residue and two negatively
charged residues that are involved in the stabilisation of the
negatively charged reaction intermediate and metal ion
coordination, respectively. As expected on the basis of the
proposed alignment, mutation of K292 (mutant K292R and
K292M) strongly affected cN-II activity. Similarly, muta-
tion of two aspartate residues (D351 and D356) resulted in
very poor phosphatase and phosphotransferase activities
and significantly reduced affinity towards Mg2+. As
expected, conservative mutations (mutant D351E and
D356E) had a less pronounced effect than non-conservative
mutations. Furthermore, D356N showed a tenfold increase
of the Km value for inosine, suggesting a possible role for
this amino acid in the interaction with the second substrate.
All these data confirmed the nature of the residues present
in motif III as deduced by sequence alignment.
A general comparison of all kinetically characterised
mutants showed that the phosphatase vs phosphotransferase
activity ratio was significantly altered in two cases: mutant
S251T and mutant M53I. In the first case this phenomenon
was not justified simply on the basis of the slight alterations
of Km value measured for both substrates. In the latter case
the observed value for this parameter was in line with the
tenfold increase of Km for IMP. A model of the cN-II active
Table 2 Amino acid sequence of the cN-II three motifs involved in
the active site. Amino acid residues that have been mutated are
indicated in bold type.
Motif Amino acid sequence
Motif I 51 DMDYTL
Motif II 244 VFLATNS
Motif III 291K.....347 YIGDHIFGDIL
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site structure, designed on the basis of our results, is
presented in Figure 1.
Physiological aspects of cN-II
The apparent inhibition of cN-II by its product inosine [22]
led to the discovery of the exchange of the nucleoside
moiety between inosine and IMP and to the proposal that
cN-II catalyses the transfer of the phosphate group of IMP
to inosine by forming a phosphorylated enzyme as
intermediate [17]. Studies on the enzyme–substrate speci-
ficity revealed that cN-II may, indeed, utilise IMP as
phosphate donor for a number of nucleosides and nucleo-
side analogues, such as 20-30-dideoxyinosine and 8-azagua-
nosine [3, 23]. The respective importance of hydrolase and
phosphotransferase activities of cN-II in cellular metabo-
lism is unclear. The reader is referred to the recent review
of Bretronnet et al. [24] for a discussion on this important
functional aspect of cN-II. At least in vitro, cN-II mediated
xanthosine (Xao) phosphorylation (IMP + Xao → XMP +
Ino) appears to be the only possible pathway for salvaging
Xao [25]. This reaction can bypass the NAD+-mediated
reduction of IMP into XMP, catalysed by IMP dehydroge-
nase (IMPDH), an enzyme targeted for human antiviral,
immunosuppressive, and antineoplastic chemotherapy [26,
27]. cN-II may also enable dIMP formation from IMP as a
donor and deoxyinosine as an acceptor of phosphate, fol-
lowed by conversion of dIMP to dAMP or dGMP. This
pathway bypasses the ribonucleotide reductase activity [14].
cN-II is involved in the maintenance of the intracellular
PRPP pool through the oxypurine cycle
The regulation of PRPP synthesis by PRPP synthetase and
its utilisation by the phosphoribosyl transferases are the
major factors maintaining the intracellular level of PRPP, a
high-energy sugar phosphate, with a high potential of 5-
phosphoribosyl transfer [28]. An additional factor is the
“oxypurine cycle,” also named the “purine nucleoside
cycle” [29] The oxypurine cycle is a cyclic pathway,
composed of hypoxanthine-guanine phosphoribosyltrans-
ferase (HPRT) nucleoside phosphorylase and the cN-II
(Figure 2). Because its net reaction is the hydrolysis of
PRPP, the cycle has been proposed to play a role in the
metabolic regulation of intracellular PRPP levels [30]. Rat
brain cytosol is particularly suitable for investigating the
kinetics of the cycle, because neither IMP nor inosine acts
as a substrate of ATP-mediated kinases [10, 31], and
xanthine oxidase is virtually absent in rat brain [32]. As
evidenced in Figure 2, the velocity of the “oxypurine
cycle,” and, therefore, the rate of PRPP disappearance and
ribose-1-phosphate (Rib 1-P) formation, is modulated by
ATP, acting as an activator of cN-II, and by Pi, acting as an
inhibitor. (2,3-bis-phosphoglycerate (2,3-BPG) may substi-
tute ATP as an activator.
Studies on the kinetics of the in vitro reconstituted cycle
and in rat brain cytosolic preparations [10] have shown that
the three components, IMP, inosine and hypoxanthine,
attain a steady-state level. Strikingly, at the end of this
steady state period, whose duration depends on the initial
PRPP concentration, hypoxanthine abruptly accumulates, at
the expense of IMP degradation (Figure 3). We explain
these results as follows. While PRPP is being degraded to
inorganic pyrophosphate (PPi) and Rib 1-P, the intermediates
are continuously recycled, but, as soon as PRPP disappears,
HPRT becomes inactive. Then the cycle “collapses”, causing
IMP degradation by cN-II, and hypoxanthine accumulation
by purine nucleoside phosphorylase. As a consequence, the
duration of the state–state period may be considered as a
measure of the rate of the PRPP consumption. The velocity
of the cycle, as measured by the rate of PRPP disappearance,
responds to protein concentration as well as to the allosteric
activators of cN-II and to Pi, the allosteric inhibitor. We
conclude that modulation of cN-II might, in turn, regulate the
Figure 1 Schematic representation of the proposed active site of cN-
II. Modified from Allegrini et al., 2004 [9]
Figure 2 The oxypurine cycle. The enzymes participating in the cycle
are: 1 HPRT; 2 cN-II; 3 purine nucleoside phosphorylase (PNP). The
net reaction is the hydrolysis of 5-PRPP to Rib 1-P and inorganic
pyrophosphate (PPi). The allosteric activation by ATP and 2-3-BPG,
and the inhibition by Pi, modulate the cycle rate. Modified from Leach
et al., 1998 [33]
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oxypurine nucleoside cycle. It might be speculated that, at
normal low [Pi]/[ATP] ratios, as found in well-oxygenated
cells, cN-II is fully active, and the velocity of the cycle is
maximal. As a consequence the PRPP pool is maintained at a
low level, thus avoiding unnecessary salvage or de novo
nucleotide synthesis. During ischaemia, the [Pi]/[ATP] ratio
rises drastically [33, 34], the situation is reversed, and
enough PRPP is made available for purine nucleotide
salvage and/or synthesis during reperfusion. This process,
which in our opinion represents the real purine salvage, is
favoured by the increase in purine base levels occurring in
ischaemia [34] and by the increase in PRPP that accom-
panies massive ATP degradation, as it occurs in rat brain
during anoxia-like conditions [35].
A widely accepted tenet is that, under normal conditions,
the PRPP pool is maintained at a low level, to avoid
excessive and unbalanced nucleotide synthesis. We notice
PRPP, the “fuel” of the cycle, is an obligate precursor of
purine salvage, while Rib 1-P, one of the cycle products
(Figure 2) may be used for uracil salvage and 5-fluorouracil
(5-FU) activation, a process involving pyrimidine base (or
base analogue) ribosylation, catalysed by uridine phosphor-
ylase, followed by multiple phosphorylation steps [36–39].
The observation that uracil is readily converted into uridine
in the presence of PRPP, in the absence of any detectable
uracil phosphoribosyltransferase activity and provided that
hypoxanthine is present in the reaction mixture, led to the
proposal that Rib 1-P needed to ribosylate uracil or 5-FU
might well arise from PRPP breakdown occurring in the
oxypurine cycle.
Modulation of adenylate deaminase and cN-II affects
adenosine production in rat brain
Adenosine is a neuroactive nucleoside and a homoeostatic
cellular modulator. Its main source is ATP breakdown [40].
Figure 4 Pathways of intracellular ATP catabolism in rat brain. The
enzymes participating in these pathways are: 1 adenylate kinase, 2
adenylate deaminase, 3 cytosolic IMP-GMP specific 50-nucleotidase
(cN-II), 4 purine nucleoside phosphorylase, 5 cytosolic AMP specific
5′nucleotidase, 6 adenosine deaminase. Enzymes 2 and 3 are activated
by physiological ATP concentrations. Modified from Barsotti and
Ipata, 2004 [11]
Figure 3 The oxypurine cycle as catalysed by rat brain extract. The
reaction mixture contained 100 μM [14C]-inosine, 1 mM PRPP
(closed symbols) or 2 mM PRPP (open symbols), 5 mM KH2PO4,
8.3 mM MgCl2, 4.5 mM BPG, 5 mM Tris-HCl buffer, pH 7.4, and a
brain cytosolic preparation, 1.15 mg of protein/ml. Circles hypoxan-
thine, triangles inosine, squares IMP. The dotted line represents the
time course of PRPP disappearance at 2 mM initial concentration.
During PRPP consumption the three components of the cycle attain a
steady-state level whose duration depends on the initial PRPP
concentration, suggesting that, during PRPP degradation to PPi and
Rib-1-P, the intermediates are continuously recycled. Modified from
Barsotti et al., 2003 [10]
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While extracellular ATP breakdown follows a unique
pathway, composed of a set of membrane-bound ecto-
nucleotidases, intracellular ATP breakdown follows two
distinct routes [11] (Figure 3). In the first route, ATP ↔
ADP ↔ AMP interconversion, catalysed by adenylate
kinase, is followed by AMP deamination and cN-II-mediated
IMP dephosphorylation (the “IMP pathway”). In the second
route, AMP is dephosphorylated by the AMP preferring
cytosolic 50-nucleotidase cN-1A (cytosolic AMP preferring
50-nucleotidase, form A) to adenosine, and adenosine is
deaminated to inosine (the “adenosine pathway”). Recent
studies [11] have established that the nature of the ATP
catabolic route (i.e., if it follows the IMP or the adenosine
pathway) is concentration dependent. Thus, at 3.6 mM (a
normoxic concentration), ATP breakdown follows the IMP
pathway, with little, if any, adenosine production. Moreover,
IMP, but not AMP or adenosine, accumulates in cytosolic
preparations of rat brain. This can be explained by the de-
activation of cN-II, prompted by the disappearance of ATP,
an allosteric activator of the enzyme. (Figure 4). This
condition also increases the Km value for the substrate IMP
from micromolar to millimolar value [8]. Moreover, the
production of the small amount of adenosine after prolonged
incubation was clearly preceded by inosine and hypoxan-
thine formation, thus excluding a precursor–product rela-
tionship between adenosine and inosine plus hypoxanthine.
Any inosine and hypoxanthine would, therefore, originate
from IMP, rather than adenosine. We have proposed that, as
far as intracellular ATP is maintained at normoxic concen-
tration, its catabolism follows the IMP pathway, and only a
minimal amount of adenosine, if any, is generated in rat brain
from ATP. As a consequence, the ratios of the inosine plus
hypoxanthine levels to adenosine cannot be considered to
indicate the rate of metabolic degradation from adenosine to
inosine and hypoxanthine in normoxic conditions. This view
is in accordance with the strong activation exerted by
physiological ATP concentration on both adenylate deami-
nase and cN-II [41–43]. It is also supported by the low Km
value of adenosine kinase for adenosine, as compared to that
of adenosine deaminase. Accordingly, adenosine at 1 μM, a
reasonable physiological normoxic concentration, is anabol-
ised mostly to AMP, ADP and ATP, rather than catabolised
to inosine. Only at higher concentrations is adenosine
catabolised into inosine and hypoxanthine [11].
At an initial concentration of 0.5 mM, AMP immediately
and transiently accumulates, followed by an accumulation of
adenosine, inosine and hypoxanthine. This suggests a
precursor–product product relationship between AMP and
adenosine, inosine and hypoxanthine and explains the
apparently paradoxical observation that more adenosine is
produced at 0.5 mM than at 3.6 mM initial ATP concentra-
tion [11]. Hydrolysis by S-adenosylmethionine hydrolase,
another possible source of adenosine, does not significantly
contribute to adenosine production in rat brain [44, 45].
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